BURBANK, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Imaging3™, Inc. (the “Company”) (OTCQB:IGNG) announced today that the Company’s common stock will commence trading on the OTCQB marketplace under the trading symbol “IGNG”. The OTCQB is part of the quality controlled segment of the over-the-counter market, available only to SEC reporting companies or federally regulated banking companies which are current in their regulatory filing requirements and maintain a minimum bid price.
Dane Medley, Chairman/CEO of Imaging3 commented, “We are pleased that OTCMarkets has approved our OTCQB application, and in so doing allows our shareholders to hold and trade our common stock on an accredited exchange. We view this as a significant step forward for the Company and are especially gratified that we have been able to obtain the OTCQB approximately 10 weeks after our 15c2-11 filing was approved and our stock commenced trading on the OTCPink market after the four-year hiatus caused by our successful Chapter 11 reorganization. We believe this will help build momentum as we strive toward our goal of obtaining FDA 510K approval of our technology.”
The Company intends to provide ongoing updates of relevant material information to the public in the form of appropriate filings and press releases, all of which will be available on EDGAR, the OTCMarkets website and our Company website, www.imaging3.com.
Imaging3, Inc., founded in 1993, has developed a patented medical imaging technology that will produce 3D medical diagnostic images in real time in each of single 3D SafeScan, Continuous 3D Scan and CT SafeScan mode. The Company’s technology will allow healthcare professionals utilizing Imaging3 lightweight portable devices to view 3D, high resolution images of virtually any part of the human body in real time, even as they are performing procedures. The technology utilizes high resolution fluoroscopy to construct 3D images in real time. Such images are useful in helping health care professionals safely perform procedures on or in the human body. In addition, the Company’s technology exposes patients to significantly less harmful radiation than current imaging technologies such as CT scans. The Company believes this lower radiation exposure allow scans to be used in more pediatric applications than are currently prescribed. Perhaps most important, the Company believes that its technology will significantly reduce the cost of essential imaging to the healthcare system. The Company’s technology and imaging devices based upon it may not be used in human applications in the United States until the Company obtains FDA 510K approval of specific applications of its technology. However, the Company has not yet reapplied for FDA approval of any application of its technology (which FDA approval was denied in 2013) and there can be no assurance that the Company will obtain sufficient funding to reapply for any FDA approval or that, even if such funding is achieved, the Company will ever receive FDA approval of any possible application of its technology.
Visit the company’s website at http://www.imaging3.com for detailed information about the Company’s technology.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may" "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, failure to consummate desired business combinations or transactions, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently, unavailability of financing for the Company or its customers, product malfunction, potential product liability claims, and other factors detailed in reports filed by the Company.
Investor Relations Contact: Amato and Partners, LLC 90 Park Avenue, 17th Floor New York, NY 10016 firstname.lastname@example.org